BR0112674A - Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors - Google Patents

Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors

Info

Publication number
BR0112674A
BR0112674A BR0112674-1A BR0112674A BR0112674A BR 0112674 A BR0112674 A BR 0112674A BR 0112674 A BR0112674 A BR 0112674A BR 0112674 A BR0112674 A BR 0112674A
Authority
BR
Brazil
Prior art keywords
oxazolyl
thiazolyl
alkyl
dependent kinases
cyclin
Prior art date
Application number
BR0112674-1A
Other languages
Portuguese (pt)
Inventor
Raj N Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0112674A publication Critical patent/BR0112674A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INIBIDORES N-[5-[[[5-ALQUIL-2-OXAZOLIL] METIL] TIO]-2-TIAZOLIL] CARBOXAMIDA DE QUINASES DEPENDENTES DE CICLINA". A presente invenção descreve compostos da fórmula: e os enantiomorfos, diastereoisómeros, solvatos e sais farmaceuticamente aceitáveis dos mesmos. Os compostos da fórmula são inibidores de proteína quinase e são úteis no tratamento de doenças proliferativas, por exemplo, câncer, inflamação e artrite. Eles também podem ser de utilidade para o tratamento da doença de Alzheimer, alopécia induzida por quimioterapia, e doença cardiovascular."N- [5 - [[[[5-ALKYL-2-OXAZOLYL] METHYLE] UNIO] -2-THIAZOLYL] CARBOXAMIDE OF CYCLINE DEPENDENT KINASES". The present invention describes compounds of the formula: and the pharmaceutically acceptable enantiomorphs, diastereoisomers, solvates and salts thereof. The compounds of the formula are protein kinase inhibitors and are useful in treating proliferative diseases, for example cancer, inflammation and arthritis. They may also be of use for the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.

BR0112674-1A 2000-07-26 2001-05-09 Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors BR0112674A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles
PCT/US2001/015081 WO2002010162A1 (en) 2000-07-26 2001-05-09 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
BR0112674A true BR0112674A (en) 2003-12-30

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112674-1A BR0112674A (en) 2000-07-26 2001-05-09 Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors

Country Status (26)

Country Link
EP (1) EP1303513A1 (en)
JP (1) JP2004509857A (en)
KR (1) KR20030016429A (en)
CN (1) CN100457753C (en)
AR (1) AR030563A1 (en)
AU (1) AU2001259704A1 (en)
BG (1) BG65132B1 (en)
BR (1) BR0112674A (en)
CA (1) CA2417254A1 (en)
CZ (1) CZ2003237A3 (en)
EE (1) EE200300041A (en)
EG (1) EG24409A (en)
GE (1) GEP20043367B (en)
HR (1) HRP20030116A2 (en)
HU (1) HUP0303698A2 (en)
IL (2) IL153591A0 (en)
LV (1) LV13037B (en)
MX (1) MXPA03000774A (en)
MY (1) MY129635A (en)
NO (1) NO20030394L (en)
PL (1) PL365170A1 (en)
SI (1) SI21099A (en)
SK (1) SK18392002A3 (en)
TW (1) TWI302533B (en)
WO (1) WO2002010162A1 (en)
YU (1) YU4903A (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
KR20050057072A (en) 2002-09-04 2005-06-16 쉐링 코포레이션 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
RU2380369C9 (en) 2002-09-04 2011-07-10 Шеринг Корпорейшн Novel pyrazolopyrimidines as inhibitors of cyclin-dependant kinase
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
JP2006503838A (en) 2002-09-23 2006-02-02 シェーリング　コーポレイション A novel imidazopyrazine as a cyclin-dependent kinase inhibitor
PE20050081A1 (en) 2002-09-23 2005-03-01 Schering Corp NEW IMIDAZOPYRAZINES AS INHIBITORS OF CYCLINE-DEPENDENT KINASES
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (en) * 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
WO2007022258A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
JP2009507843A (en) 2005-09-09 2009-02-26 シェーリング コーポレイション Aza-fused cyclin-dependent kinase inhibitors
CN101321760A (en) 2005-10-06 2008-12-10 先灵公司 Pyrazolopyrimidines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
JP2009539846A (en) * 2006-06-06 2009-11-19 ブリストル−ミエルス スクイッブ カンパニー Crystalline form of N- [5-[[[5- (1,1-dimethylethyl) -2-oxazolyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide
US9206142B2 (en) 2006-10-31 2015-12-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
US8318735B2 (en) 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CN101678002A (en) 2007-05-08 2010-03-24 先灵公司 Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
EP2831282B1 (en) 2012-03-30 2018-07-04 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
WO2015081867A1 (en) * 2013-12-04 2015-06-11 杭州民生药物研究院有限公司 Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
TWI302533B (en) 2008-11-01
BG65132B1 (en) 2007-03-30
LV13037B (en) 2003-11-20
EG24409A (en) 2009-05-20
CA2417254A1 (en) 2002-02-07
PL365170A1 (en) 2004-12-27
AR030563A1 (en) 2003-08-27
SI21099A (en) 2003-06-30
WO2002010162A1 (en) 2002-02-07
AU2001259704A1 (en) 2002-02-13
GEP20043367B (en) 2004-06-10
IL153591A0 (en) 2003-07-06
SK18392002A3 (en) 2003-09-11
MXPA03000774A (en) 2003-09-10
NO20030394D0 (en) 2003-01-24
KR20030016429A (en) 2003-02-26
CZ2003237A3 (en) 2003-06-18
JP2004509857A (en) 2004-04-02
YU4903A (en) 2006-03-03
NO20030394L (en) 2003-03-03
BG107468A (en) 2004-01-30
HRP20030116A2 (en) 2005-02-28
EE200300041A (en) 2005-04-15
HUP0303698A2 (en) 2004-04-28
CN100457753C (en) 2009-02-04
MY129635A (en) 2007-04-30
EP1303513A1 (en) 2003-04-23
IL153591A (en) 2009-07-20
CN1444584A (en) 2003-09-24

Similar Documents

Publication Publication Date Title
BR0112674A (en) Cyclin-dependent kinases n- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors
PT1240165E (en) INHIBITORS N- [5 - [[[5-ALKYL-2-OXAZOLYL] METHYL] THIO] -2-THIAZOLYL] CARBOXAMIDE OF CYCLINE DEPENDENT KINASES
BR0016424A (en) N- [5 - [[[5-alklyl-2-oxazolyl] methyl] -thio] -2-thiazolyl] carboxine amide inhibitors of cyclin-dependent kinases
NO20025450D0 (en) New pharmaceutical composition
GB0005251D0 (en) Therapeutic compounds
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
BR0209468A (en) Pharmaceutically acceptable compound or salts or solvates thereof, pharmaceutical composition, use of a compound, and method of treating an HPP-mediated disease or condition
BRPI0407834A (en) compound, process for the manufacture thereof, composition, process for the manufacture thereof, method of treating or preventing a protein kinase-mediated disorder in an individual, use of a compound, assay to determine the activity of the compounds, and method inhibiting the activity or function of a protein kinase
WO2002002518A3 (en) Compounds to treat alzheimer's disease
BR0207316A (en) Epothilone derivatives for the treatment of refractory tumors
PT1268472E (en) 3-AMINOPIRAZOLIC INHIBITORS OF CYCLINE DEPENDENT KINASES
NO20023486L (en) Pyrrole-type compounds, compounds containing compounds and their use in the treatment of cancer and viral diseases
DE60108626D1 (en) USE OF 5-THIO, SULFINYL AND SULFONYLPYRAZOLO 3,4-B] PYRIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS
LT2003001A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
BR0211970A (en) Use of bibn4096 in combination with other anti-migraine drugs to treat migraine.
HUP0300298A2 (en) 4-[piperazinyl-(8-quinolinyl)metyl]benzamide derivatives, their use and pharmaceutical compositions containing them
BR0211358A (en) Use of the 2- [5- (4-fluorophenyl) -3-pyridylmethylaminomethyl] -chroman compound and its physiologically acceptable salts
UY26732A1 (en) N- (5- (5-ALQUIL-2-OXAZOLIL) METHYL) UNCLE) -2- TIAZOLIL) CYCLINE DEPENDENT KITCHEN INHIBITING CARBOXAMIDS
ECSP003821A (en) INHIBITORS OF N- (5 (((5-ALQUIL-2-OXAZOLIL) METHYL) TIO) -2-TIAZOLIL) -CARBOXAMIDE OF CYCLINE-DEPENDENT KINASES
ECSP003826A (en) INHIBITORS OF N- (5 (((5-ALQUIL-2-OXAZOLIL) METHYL) TIO) -2-TIAZOLIL) -CARBOXAMIDE OF CYCLINE-DEPENDENT KINASES
TH62250A (en) N- [5 - [[[5-alkyl-2-oxasolyl] methyl] thiol] -2-thiazolyl] - carboxamid of Cyclin Dependent Kinase
FR2804867B1 (en) APPLICATION OF XANTHINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS
UY25369A1 (en) PROCEDURE FOR PREPARING PROTEASE INHIBITORS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]